文献速递贫血与红细胞疾病血栓与止血白血病

ASH-ASPHO明智选择运动:5项应质疑的血液学检验与治疗

The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.
PubMed 文献 · Blood Adv · 2022-01-01

美国血液学会(ASH)与美国儿科血液学/肿瘤学会(ASPHO)联合工作组采用迭代流程与循证方法,遴选5项缺乏证据支持或风险成本高而获益可能性低的儿科血液学检验与治疗,建议医护人员在实施前仔细权衡预期风险与获益。

要点

  • 对无出血个人史或家族史的健康儿童,避免常规术前止血检测。
  • 无症状且血小板计数>10×10³/μL的儿童,除非计划侵入性操作,避免输注血小板。
  • 儿童静脉通路相关血栓且无阳性家族史者,避免血栓形成倾向检测。

核心结论

  • ASH-ASPHO工作组识别出5项应被质疑的儿科血液学检验与治疗,因其缺乏证据支持或风险与医疗成本高而获益可能性低。
  • 推荐医护人员在实施这些检验与治疗前仔细考虑预期风险与获益。

研究设计与样本

  • ASH与ASPHO于2019年成立联合工作组,采用迭代流程与循证方法遴选儿科明智选择清单项目。

主要发现

  • 工作组共识别出5项应被质疑的血液学检验与治疗。

关键数值与推荐

  • 避免对无出血个人史或家族史的健康儿童常规进行术前止血检测。
  • 避免对无症状且血小板计数>10×10³/μL的儿童输注血小板,除非计划侵入性操作。
  • 避免对静脉通路相关血栓且无阳性家族史的儿童进行血栓形成倾向检测。
  • 避免对无症状缺铁性贫血且无活动性出血的儿童输注浓缩红细胞。
  • 避免对无症状自身免疫性中性粒细胞减少且无反复或严重感染史的儿童常规预防性使用粒细胞集落刺激因子。

临床怎么用

  • 原文推荐医护人员在实施上述5项检验与治疗前仔细考虑预期风险与获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Choosing Wisely is a medical stewardship and quality-improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The American Society of Hematology (ASH) has been an active participant in the Choosing Wisely project. In 2019, ASH and the American Society of Pediatric Hematology/Oncology (ASPHO) formed a joint task force to solicit, evaluate, and select items for a pediatric-focused Choosing Wisely list. By using an iterative process and an evidence-based method, the ASH-ASPHO Task Force identified 5 hematologic tests and treatments that health care providers and patients should question because they are not supported by evidence, and/or they involve risks of medical and financial costs with low likelihood of benefit. The ASH-ASPHO Choosing Wisely recommendations are as follows: (1) avoid routine preoperative hemostatic testing in an otherwise healthy child with no previous personal or family history of bleeding, (2) avoid platelet transfusion in asymptomatic children with a platelet count >10 × 103/μL unless an invasive procedure is planned, (3) avoid thrombophilia testing in children with venous access-associated thrombosis and no positive family history, (4) avoid packed red blood cells transfusion for asymptomatic children with iron deficiency anemia and no active bleeding, and (5) avoid routine administration of granulocyte colony-stimulating factor for prophylaxis of children with asymptomatic autoimmune neutropenia and no history of recurrent or severe infections. We recommend that health care providers carefully consider the anticipated risks and benefits of these identified tests and treatments before performing them.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. O'Brien SH, Badawy SM, Rotz SJ, et al. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Adv. 2022. PMID: 35072726. doi:10.1182/bloodadvances.2020003635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。